Now I have all the information needed. Here's a concise summary of all three documents:
Patient: Mrs. Ayesha Khatoon, 55F | Max Starlit Medical Centre, Lucknow | Ref: Dr. Kamlesh Verma
📄 Report 1 — Lab Investigations (12 May 2026)
Liver Function Test (LFT)
- Globulin slightly elevated (4.1; ref 3.0–3.7)
- ALP high: 137 U/L (ref 35–105)
- GGT high: 89.6 U/L (ref 1–40)
- Other liver parameters (bilirubin, AST, ALT, albumin, total protein) — within normal limits
HbA1c — 5.30% ✅ Normal (pre-diabetic threshold is 5.7%)
Renal Function Test (RFT)
- Creatinine slightly elevated: 1.3 mg/dL (ref 0.4–1.2)
- Potassium mildly high: 5.26 mmol/L (ref 3.5–5.1)
- Phosphorus mildly high: 4.73 mg/dL (ref 2.5–4.5)
- Sodium slightly low: 135.3 mmol/L (ref 136–145)
- Uric acid elevated: 6.96 mg/dL (ref 2.4–5.7)
- Urea, BUN, Chloride, Calcium — normal
Coagulation (PT/APTT) — Normal
CBC (Complete Blood Count)
- Haemoglobin mildly low: 11.4 g/dL (ref 12–15) — mild anaemia
- Lymphocytes mildly low: 17.3% (ref 20–40)
- All other counts within normal limits
Tumour Markers
- CEA elevated: 10.1 ng/mL (ref 0–4.7) 🔴 Significantly high
- CA 19.9: <2.00 U/mL ✅ Normal
Thyroid Profile
- TSH low: 0.126 uIU/mL (ref 0.27–4.2) — subclinical hyperthyroidism
- T3, T4 — within normal limits
Viral Markers — HCV, HBsAg, HIV — all Non-Reactive ✅
📄 Report 2 — Chromogranin A (13 May 2026)
- Chromogranin A: 346.16 µg/L 🔴 (ref 0–100) — markedly elevated
- Significant for neuroendocrine tumour (NET), carcinoid, pheochromocytoma, or functioning islet/GI tumour
📄 Document 125 — PET-CT Whole Body (13 May 2026)
Clinical context: Upper abdominal pain and vomiting for 2 months. Prior CT (07 May 2026) showed a pancreatic mass and multiple liver lesions.
Key Findings:
- 🔴 Primary malignancy in pancreas — Hypermetabolic (FDG-avid) partially necrotic soft tissue lesion in the distal body and tail of pancreas (size ~2.5 × 4.9 × 3.2 cm, SUVmax 7.92), extending into peripancreatic fat, abutting lesser curvature of stomach and splenic artery
- 🔴 Liver metastases — Multiple hypermetabolic hypodense lesions in both lobes of liver (largest ~1.5 × 1.8 cm, SUVmax 14.29 in segment II)
- 🔴 Peripancreatic lymph node metastasis (~1.3 × 1.0 cm, SUVmax 5.02)
- ⚠️ Non-FDG-avid fibronodular lesions in bilateral lungs — nature unclear, needs follow-up
- ⚠️ Breast lesions (left fibronodular; right nodular ~0.9 × 1.0 cm) — nature unclear, mammography recommended
- Left axillary lymph node — mildly FDG avid, likely inflammatory
- Degenerative spinal changes (cervical, dorsal, lumbar)
- No brain or mediastinal metastasis detected
🔑 Overall Summary
Mrs. Ayesha Khatoon has findings consistent with a pancreatic neuroendocrine tumour (pNET) or pancreatic malignancy with hepatic and nodal metastases, supported by:
- Markedly elevated Chromogranin A (346 µg/L) — a hallmark NET marker
- Elevated CEA (10.1 ng/mL)
- PET-CT confirming a hypermetabolic pancreatic tail mass with liver and peripancreatic lymph node metastases
Histopathological confirmation is recommended as per the PET-CT report. Further workup for the lung and breast lesions is also advised.